Volume 5, Issue 4
Editorialp. 355–357
The adaptive trial opportunity for biotechs and smaller pharmaceutical companies
Author(s): Tom Parke
Opinion Articlep. 359–361
Adaptive clinical trials and their potential to improve drug-development efficiency
Author(s): Christopher J Weir
Commentaryp. 363–366
Adaptive designs for Phase II oncology trials
Author(s): Meinhard Kieser, Stefan Englert, Geraldine Rauch
Commentaryp. 367–371
Novel adaptive designs: aligning drug development and patient incentives
Author(s): John W Loewy
Clinical Trail Perspectivep. 373–381
Monitoring rules for toxicity in Phase II oncology trials
Author(s): Anastasia Ivanova, Guochen Song, Olga Marchenko & Stergios Moschos
Clinical Trail Methodologyp. 383–391
Adaptive enrichment designs: applications and challenges
Author(s): Noah Simon
Clinical Trail Methodologyp. 393–399
Multi-arm clinical trials with treatment selection: what can be gained and at what price?
Author(s): Thomas Jaki
Clinical Trail Methodologyp. 401–413
Using simulation to optimize adaptive trial designs: applications in learning and confirmatory phase trials
Author(s): Jurgen Hummel, Song Wang & John Kirkpatrick
Clinical Trail Methodologyp. 415–425
Statistical inference of adaptive randomized clinical trials for personalized medicine
Author(s): Feifang Hu, Yanqing Hu, Wei Ma, Lixin Zhang & Hongjian Zhu
